RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Table 2

Mutation types of RAS/BRAF detected in 76 patients.

Gene	Mutation	Tissue			Plasma
		Synchronous group	Metachronous group	Total	Synchronous group	Metachronous group	Total
KRAS	G12A, G12C, G12D,; G12V, G13D, G13S	26.32%; (5/19)	45.24%; (19/42)	39.34%; (24/61)	35.42%; (17/48)	14.29%; (4/28)	27.63%; (21/76)
KRAS	Q61H, Q61K	5.26%; (1/19)	0%; (0/42)	1.64%; (1/61)	0%; (0/48)	10.71%; (3/28)	3.95%; (3/76)
KRAS	A146T	0%; (0/19)	0%; (0/42)	0%; (0/61)	0%; (0/48)	3.57%; (1/28)	1.32%; (1/76)
NRAS	G12V, G12D	5.88%; (1/17)	0%; (0/39)	1.79%; (1/56)	2.08%; (1/48)	0%; (0/28)	1.32%; (1/76)
NRAS	Q61R, Q61K	0%; (0/17)	7.69%; (3/39)	5.36%; (3/56)	2.08%; (1/48)	0%; (0/28)	1.32%; (1/76)
BRAF	Y472F, P403fs	0%; (0/18)	0%; (0/40)	0%; (0/58)	2.08%; (1/48)	3.57%; (1/28)	2.63%; (2/76)
HRAS	G12D	/	/	/	2.08%; (1/48)	0%; (0/28)	1.32%; (1/76)
HRAS	P167fs	/	/	/	2.08%; (1/48)	3.57%; (1/28)	2.63%; (2/76)